杨小鼙
Lv1
30 积分
2021-03-25 加入
-
中国恶性肿瘤整合诊治指南-直肠癌部分
2个月前
已完结
-
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
3个月前
已完结
-
Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial
3个月前
已完结
-
Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
3个月前
已完结
-
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
4个月前
已完结
-
Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients With Resectable NSCLC: A Phase 2 Clinical Trial
4个月前
已完结
-
Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial
4个月前
已完结
-
Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine phase III randomized controlled clinical trial for patients with locally advanced gastric adenocarcinoma: long-term results of a randomised controlled trial
5个月前
已完结
-
美托洛尔及厄贝沙坦氢氯噻嗪在老年重症心力衰竭急诊内科治疗中的应用
6个月前
已完结
-
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
6个月前
已完结